Glucagon-like-peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are the two main incretins
Its hard to predict the future, but I think theres real cause for optimism The pipeline of these drugs is massive and the trials to date have been incredibly encouraging
You don't want to be locked into a rigid meal plan delivery
Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA) Japan, Medicines and Healthcare products Regulatory Agency (MHRA) UK, National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), Centers for Disease Control and Prevention (CDC) National Diabetes Statistics Report, World Health Organization (WHO) Global Health Observatory, International Diabetes Federation (IDF) Diabetes Atlas, American Diabetes Association (ADA) Standards of Care, European Association for the Study of Diabetes (EASD) Guidelines, IQVIA Institute for Human Data Science, Evaluate Pharma, and national health ministry reports from key markets (China NMPA, India CDSCO, Brazil ANVISA)
Therefore, DPPIV inhibitors might promote glucoregulation in part because of resulting elevated levels of PYY 1-36 , albeit with associated losses in food intake and body weight reduction
